AGC Biologics

AGC Biologics is a global Contract Development and Manufacturing Organization (CDMO) focused on biopharmaceuticals. Established in January 2018, it emerged from the merger of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics. The company is part of the AGC Inc. group, which has a rich history dating back to 1907. The company provides a wide range of development and manufacturing services for therapeutic proteins, plasmid DNA, messenger RNA, viral vectors, and genetically engineered cells. AGC Biologics supports clients in various phases of production, from early to late-stage and commercial needs, while adhering to current Good Manufacturing Practice (cGMP) standards. With facilities in the United States, Europe, and Japan, AGC Biologics serves a diverse clientele in the biopharmaceutical sector, including those working on advanced therapies like gene and cell therapies.